MX2018009558A - Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfon il-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-m etilbenzoil)guanidina. - Google Patents

Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfon il-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-m etilbenzoil)guanidina.

Info

Publication number
MX2018009558A
MX2018009558A MX2018009558A MX2018009558A MX2018009558A MX 2018009558 A MX2018009558 A MX 2018009558A MX 2018009558 A MX2018009558 A MX 2018009558A MX 2018009558 A MX2018009558 A MX 2018009558A MX 2018009558 A MX2018009558 A MX 2018009558A
Authority
MX
Mexico
Prior art keywords
bismethanesulfonyl
guanidine
hylbenzoyl
methylbe
nzoyl
Prior art date
Application number
MX2018009558A
Other languages
English (en)
Inventor
Saal Christoph
Becker Axel
Kuehn Clemens
Gallon Gilmary
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2018009558A publication Critical patent/MX2018009558A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/06—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con nuevas modificaciones cristalinas de clorhidrato de N-(4,5-bismetansulfonil-2-metilbenzo il)guanidina, nuevas sales de N-(4,5-bismetansulfonil-2-metilbenzo il)guanidina y sus modificaciones cristalinas y procesos de manufactura y sus formulaciones farmacéuticas.
MX2018009558A 2016-02-08 2017-01-27 Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfon il-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-m etilbenzoil)guanidina. MX2018009558A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16154672 2016-02-08
PCT/EP2017/000102 WO2017137147A1 (en) 2016-02-08 2017-01-27 Crystalline modifications of n-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine hydrochloride and n-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine salts

Publications (1)

Publication Number Publication Date
MX2018009558A true MX2018009558A (es) 2018-09-06

Family

ID=55349673

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009558A MX2018009558A (es) 2016-02-08 2017-01-27 Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfon il-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-m etilbenzoil)guanidina.
MX2021010016A MX2021010016A (es) 2016-02-08 2018-08-06 Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfon il-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-m etilbenzoil)guanidina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010016A MX2021010016A (es) 2016-02-08 2018-08-06 Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfon il-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-m etilbenzoil)guanidina.

Country Status (9)

Country Link
US (1) US10981864B2 (es)
EP (2) EP4289420A3 (es)
JP (1) JP7050005B2 (es)
CN (2) CN117304079A (es)
AU (1) AU2017217728B2 (es)
CA (2) CA3013648C (es)
MX (2) MX2018009558A (es)
RU (1) RU2018131500A (es)
WO (1) WO2017137147A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19529612A1 (de) * 1995-08-11 1997-02-13 Merck Patent Gmbh Sulfonyl- oder Sulfinyl-benzoylguanidin-Derivate
DE19951418A1 (de) 1999-10-26 2001-05-03 Merck Patent Gmbh Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid
JP5634985B2 (ja) * 2008-05-09 2014-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ インスリン抵抗性およびβ−細胞機能障害に関連する疾患を治療するためのリメポリドを含む医薬組成物

Also Published As

Publication number Publication date
EP3414225A1 (en) 2018-12-19
CA3228796A1 (en) 2017-08-17
CA3013648A1 (en) 2017-08-17
AU2017217728A1 (en) 2018-09-13
JP2019506455A (ja) 2019-03-07
MX2021010016A (es) 2021-09-14
CA3013648C (en) 2024-03-19
EP4289420A2 (en) 2023-12-13
RU2018131500A3 (es) 2020-07-30
CN117304079A (zh) 2023-12-29
JP7050005B2 (ja) 2022-04-07
AU2017217728B2 (en) 2021-05-20
EP4289420A3 (en) 2024-05-15
RU2018131500A (ru) 2020-03-10
WO2017137147A1 (en) 2017-08-17
CN108602767A (zh) 2018-09-28
US10981864B2 (en) 2021-04-20
US20190345100A1 (en) 2019-11-14
EP3414225B1 (en) 2023-10-25
EP3414225C0 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
PH12016501813B1 (en) 1,3-benzodioxole derivative
WO2016172496A8 (en) Lsd1 inhibitors and uses thereof
PH12016502461A1 (en) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide hydrochloride salts
PH12016501310A1 (en) Pharmaceutical compositions comprising azd9291
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
MX2020002271A (es) Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas.
MX2017014035A (es) Formas solidas novedosas.
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
MX2018003554A (es) Benzamidas sustituidas con isoxazolina y analogos como insecticidas.
EA201891644A1 (ru) Антибактериальные соединения и их применение
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
MX2019011774A (es) N-(-1,3,4-oxadiazol-2-il)arilcarboxamidas sustituidas y su uso como herbicidas.
MX2018001517A (es) Derivados sustituidos de guanidina.
CY1123877T1 (el) Μορφες στερεας καταστασης αλατων νιλοτινιμπης
MX2017009292A (es) Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3.
BR112018075823A2 (pt) sais farmacêuticos de n-(2-(2-(dimetilamino)etoxi)-4-metoxi-5-((4-(1-metil-1h-indol-3-il)pirimidin-2-il)amino)fenil)acrilamida e suas formas cristalinas
TN2017000448A1 (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzheimer's disease
MX2021010016A (es) Modificaciones cristalinas de clorhidrato de n-(4,5-bismetansulfon il-2-metilbenzoil)guanidina y sales de n-(4,5-bismetansulfonil-2-m etilbenzoil)guanidina.
CY1124459T1 (el) Θεραπευτικος παραγοντας για δυσλειτουργια του μετωπιαιου λοβου
TR201620309A2 (tr) Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇
SA519401845B1 (ar) مركبات ألكيل أمين حلقية غير متجانسة بنزوية واستخدامها
HK1256253A1 (zh) 化合物n-(3，5-二甲基苯基)-n'-(2-三氟甲基苯基)胍的製備方法
UA106614U (uk) N-(фенілгідразидоацетил)-n'-cукцинамідоантраніламід, який виявляє протисудомну активність